Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AIM-dimer
- Development stage
- Preclinical
- Lead developer
- University of Montana
- Modality
- Small Molecules
01
Overview
AIM-dimer is a novel anthracenyl isoxazole amide (AIM) designed as a G-quadruplex (G4) DNA-binding agent. It specifically targets and binds to human telomeric G-quadruplex DNA, which inhibits the enzymatic activity of telomerase, a key factor in cancer cell proliferation and telomere maintenance. Developed by researchers at the University of Montana, AIM-dimer has demonstrated cytotoxic activity against brain tumor cell lines, including the human glioblastoma line SNB-19, with single-digit micromolar IC50 values. The compound is autofluorescent, allowing for visualization of its penetration through cell membranes and its co-localization within the nucleus. It induces apoptosis in cancer cells and represents a potential therapeutic strategy for treating malignant brain tumors.
- Other names
- anthracenyl isoxazole amide dimer
02
Targets
telomeric G4 (Telomeric DNA G-quadruplex)TERT (Telomerase)
Beyond the preview
Go deeper on AIM-dimer.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AIM-dimer.